Use of VWF-containing concentrates as a therapy which is employe

Details Use of VWF-containing concentrates as a therapy which is employe Use of VWF-containing concentrates as a therapy which is employe

1995-10-18

1996-11-05

Henley, III, Raymond

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

A61K 3800

Patent

active

055717845

ABSTRACT:
The invention relates to the administration of von Willebrand factor (vWF)-containing drugs in association with the therapeutic use of blood anticoagulants, either on their own or together with fibrinolytics. The administration, which is for the purpose of reducing the risk of hemorrhages in patients, can take place either at the same time or following the anticoagulant and lytic treatment. A therapy principle is described which separates, during therapy, the desirable effect of anticoagulation and/or fibrinolysis from the undesirable side effect of hemorrhagic tendency.

REFERENCES:
patent: 4774323 (1988-09-01), Newman et al.
patent: 5112950 (1992-05-01), Meulien et al.
patent: 5198349 (1993-03-01), Kaufman
patent: 5200510 (1993-04-01), Kumar et al.
patent: 5204323 (1993-04-01), Findlay et al.
patent: 5366869 (1994-11-01), Goldstein
patent: 5408039 (1995-04-01), Burnouf-Radosevich et al.
Tamao, Y. et al., "Effect of a Selective Thrombin Inhibitor MCI-9038 on Fibrinolysis In Vitro and In Vivo", Thrombosis and Haemostasis, 56(1):28-34(1986).
Mannucci, P. M. et al., "1-Deamino-8-D-Arginine Vasopressin: A New Pharmacological Approach to the Management of Haemophilia and Von Willebrand's Disease", The Lancet Ltd., pp. 869-872, (1977).
Lethagen, S. et al., "New Bleeding Time Devices With Retractable Blades Evaluated in Children, Healthy Volunteers and Patients With Prolonged Bleeding Time", Thrombosis and Haemostasis, 70(4):595-597(1993).
Ruggeri Z., "New Insights Into the Mechanisms of Platelet Adhesion and Aggregation", Seminars in Hematology, 31(3):229-239(1994).
Hemker H. C. et al., "Der Mechanismus der H amostase", Theoretische Voraussetzungen, pp. 1-18, (1993).
Ruggeri, Z., "von Willebrand Factor and Fibrinogen", Current Opinion in Cell Biology, 5:898-906 (1993).
Alevriadou B. R. et al., "Real-Time Analysis of Shear-Dependent Thrombus Formation and Its Blockade by Inhibitors of von Willebrand Factor Binding to Platelets", Blood, 81(5):1263-1276 (1993).
Gralnick, H. R. et al., "A Monomeric von Willebrand Factor Fragment, Leu-504-Ser-728, Inhibits von Willebrand Factor Interaction With Glycoprotein Ib-IX", Proc. Natl. Acad. Sci., 89:7880-7884 (1992).

Affiliated with

Also associated with

Rating

Use of VWF-containing concentrates as a therapy which is employe does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of VWF-containing concentrates as a therapy which is employe, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of VWF-containing concentrates as a therapy which is employe will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2015205